This is a news story, published by CNBC, that relates primarily to Maurits Pot news.
For more Maurits Pot news, you can click here:
more Maurits Pot newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
drug pricing. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Tema ETFs news, Cardiometabolic ETF news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
weight loss tradeCNBC
•67% Informative
The GLP-1 , Obesity & Cardiometabolic ETF ( HRTS ) is up 26% since its inception last November .
The firm's founder and CEO Maurits Pot thinks the winning weight loss trade isn't based on just hype.
Pot does not expect the price tag for weight loss treatments to discourage new patients.
VR Score
67
Informative language
65
Neutral language
86
Article tone
semi-formal
Language
English
Language complexity
27
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links